## Luigi Melcarne

## List of Publications by Citations

Source: https://exaly.com/author-pdf/7046110/luigi-melcarne-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

19 papers 137 d h-index g-index

23 ext. papers ext. citations 204 avg, IF L-index

#	Paper	IF	Citations
19	DOP40 Comorbidities and epidemiological risk factor but not immunosuppressive therapies increase the risk of COVID-19 in Inflammatory Bowel Disease (IBD): An ENEIDA-based, case-control study. <i>Journal of Crohn</i> and Colitis, <b>2021</b> , 15, S078-S079	1.5	78
18	Management of NSAID-associated peptic ulcer disease. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2016</b> , 10, 723-33	4.2	38
17	Prevalence, incidence and mortality of inflammatory bowel disease in Catalonia. A population-based analysis. <i>Annals of Medicine</i> , <b>2018</b> , 50, 613-619	1.5	5
16	Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 117,	0.7	4
15	Time Trends of Crohn's Disease in Catalonia from 2011 to 2017. Increasing Use of Biologics Correlates with a Reduced Need for Surgery. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	3
14	Ischemic colitis in an athlete: running is not always good for you. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2016</b> , 108, 443	0.9	2
13	Prognostic factors of liver cirrhosis mortality after a first episode of spontaneous bacterial peritonitis. A multicenter study. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2018</b> , 110, 94-101	0.9	2
12	Hypertensive panesophageal pressurization in type II achalasia. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2020</b> , 112, 76	0.9	1
11	Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Geteccu. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
10	Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial <i>Therapeutic Advances in Gastroenterology</i> , <b>2019</b> , 12, 1756284819874202	4.7	О
9	Centralization of politrauma. Study of Ferrarall reality and simulation of an agreed-upon protocol. <i>Emergency Care Journal</i> , <b>2011</b> , 7, 15	1.2	
8	Hepatic glycogenosis: a diagnostic challenge. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2017</b> , 109, 599-600	0.9	
7	P743 Time trends of Crohn disease in Catalonia from 2011 to 2017. Increasing use of biologics correlates with a reduced need for surgery. A population-based study in Catalonia. <i>Journal of Crohn</i> and Colitis, 2020, 14, S594-S594	1.5	
6	P604 Evaluation of management heterogeneity and complications of Crohn® disease in Catalonia. A population quality care study. <i>Journal of Crohn</i> ® and Colitis, <b>2021</b> , 15, S549-S550	1.5	
5	P338 effectiveness and safety of biological therapies in elderly inflammatory bowel diseases patients results from a multi center study of Geteccu. <i>Journal of Crohn</i> and Colitis, <b>2021</b> , 15, S363-S36	54 <sup>1.5</sup>	
4	P319 Impact of biological agents on postoperative complications in inflammatory bowel disease: a multicentre study of GETECCU. <i>Journal of Crohn</i> and <i>Colitis</i> , <b>2021</b> , 15, S345-S346	1.5	
3	P605 Development and validation of an objective disability index for Inflammatory Bowel Disease patients (ODIBD). <i>Journal of Crohn</i> and Colitis, <b>2021</b> , 15, S550-S551	1.5	

## LIST OF PUBLICATIONS

2	Validation of a self-reported work disability questionnaire for ulcerative colitis. <i>Medicine (United States)</i> , <b>2018</b> , 97, e12486	1.8	
1	Heterogeneity in pharmacological treatment and outcomes in Crohn's disease patients in	1.5	

Catalonia: a population-based observational study.. Annals of Medicine, 2022, 54, 1255-1264